Drug Pipeline

Insilico Medicine AI-discovered drug pipeline. 40+ total programs, 30 preclinical candidates nominated, 13 IND approvals, 6 in Phase I, 3 in Phase II, 1 Phase I complete. Zero failures.

View full pipeline on insilico.com →

Discovery

IND

Phase I

Phase II

Ph1 Done

Approved

Programs

ISM001-055

Idiopathic Pulmonary Fibrosis (IPF)

Phase II Target: TNIK

First end-to-end generative-AI-designed drug. Both target and molecule discovered by AI. Published in Nature Medicine (2025).

Rentosertib (ISM3312)

BRCA-mutant Solid Tumors

Phase II Target: USP1

USP1 inhibitor for BRCA-mutant cancers. Out-licensed to Exelixis ($80M upfront + milestones, 2023).

ISM5411

ER+/HER2- Breast Cancer

Phase II Target: KAT6A

KAT6 inhibitor for hormone receptor-positive breast cancer.

3CLPro Inhibitor

COVID-19 / Coronavirus

Phase I Complete Target: 3CLPro

Orally available covalent irreversible 3CLPro inhibitor. Phase I completed.

ISM8027

Cancer Immunotherapy (COLD Tumors)

Phase I Target: QPCTL

Glutaminyl-peptide cyclotransferase-like protein inhibitor. Novel immunotherapy for cold tumors.

ISM5939

IBD / Chronic Kidney Disease

Phase I Target: PHD

Proline hydroxylase inhibitor for inflammatory bowel disease and CKD.

ISM5059

Inflammation

Phase I Target: NLRP3

NLRP3 inflammasome inhibitor for inflammatory diseases.

MAT2A Inhibitor

MTAP-Deficient Cancer

Phase I Target: MAT2A

Methionine adenosyltransferase 2α inhibitor. Synthetic lethality for MTAP-deleted cancers.

ENPP1 Inhibitor

Anti-PD-1/L1 Resistant Cancers

Phase I Target: ENPP1

Ectonucleotide phosphodiesterase 1 inhibitor. STING pathway activation.

Menarini Partnership

Solid Tumors

Phase I Target: Undisclosed

Co-developed with Menarini Stemline Therapeutics.

ISM6331

Mesothelioma / Solid Tumors

IND-Enabling Target: TEAD

Pan-TEAD inhibitor for Hippo pathway-driven cancers.

DGKA Inhibitor

Solid Tumors

Preclinical Target: DGKA

Diacylglycerol kinase A inhibitor. Combination with checkpoint inhibitors.

CDK12/13 Inhibitor

BRCAness Induction in Tumors

Preclinical Target: CDK12

CDK12 inhibitor to induce BRCAness and sensitize tumors to PARP inhibition.

FGFR2/3 Inhibitor

Solid Tumors

Preclinical Target: FGFR2/3

Dual FGFR2/3 inhibitor for solid tumors.

KIF18A Inhibitor

Chromosomally Unstable Cancers (TP53)

Preclinical Target: KIF18A

KIF18A inhibitor targeting chromosomally unstable cancers with TP53 mutations.

WRN Inhibitor

MSI-H Cancers

Preclinical Target: WRN

WRN helicase inhibitor for microsatellite instability-high cancers.

🎯 Platform

Every program above was discovered using Insilico Medicine's end-to-end generative AI platform: PandaOmics (target discovery), Chemistry42 (generative chemistry), and InClinico (clinical trial prediction).

Source: insilico.com/pipeline · Insilico Medicine public disclosures, clinicaltrials.gov, press releases, and peer-reviewed publications.